PhaSER Biomedical Receives $2.7 Million Gates Foundation Grant Renewal for Preclinical Models and AI
PhaSER Biomedical, a preclinical and computational drug discovery firm based in Dundee, Scotland, has secured a $2.7 million (£2 million) two-year grant renewal from the Gates Foundation. This funding extends PhaSER's involvement in the Global Health Discovery Collaboratory, providing Gates Foundation grantees worldwide with access to PhaSER's humanized preclinical models and expertise in drug metabolism, pharmacokinetics (DMPK), bioanalysis, and translational study design. The renewal builds upon a previous $2.3 million Gates Foundation award granted in 2024, during which Collaboratory investigators utilized PhaSER's proprietary 8HUM humanized mouse model in global health programs targeting diseases such as tuberculosis, malaria, schistosomiasis, and Chagas disease. Professor Roland Wolf, Founder of PhaSER Biomedical, emphasized that the human-relevant data from these models can rescue promising compounds, de-risk candidates, and save valuable drug development time.
